JAK2 and myeloproliferative disorder: Since 2008, the search for the JAK2 mutation (V617T) has been included as a diagnostic criterion for myeloproliferative diseases in the guidelines of the world health Organization (WHO) and is commonly sought in patients with thrombosis splanchnic.